<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="( http://creativecommons.org/licenses/by/4.0/). Abstract MicroRNAs (miRs) have emerged as biomarkers of" exact="migraine" post="disease in both adults and children. In this study"/>
 <result pre="saliva of young subjects (age 11 ± 3.467 years) with" exact="migraine" post="without aura (MWA), while some underwent pharmacological treatment, and"/>
 <result pre="[ 1]. NSAIDs represent the first line treatment for acute" exact="migraine" post="attack [ 2, 3, 4], but their use can"/>
 <result pre="choice of treatment, to monitor the improvement or worsening of" exact="migraine" post="symptoms during the treatment and to determine the appropriate"/>
 <result pre="(CGRP) [ 9], since its serum level increases during acute" exact="migraine" post="attack [ 10] and decreases upon treatment with onabotulinumtoxin"/>
 <result pre="migraine-headache, that plasma CGRP level could be able to differentiate" exact="migraine" post="from non-migraine headache. However, other authors reported that it"/>
 <result pre="modification in chronic neuropathic pain [ 19, 20] and in" exact="migraine" post="[ 21, 22] and represent a functional interplay between"/>
 <result pre="25] described an increased expression of has-miR-34a-5p in patients with" exact="migraine" post="attacks, while Chen et al. [ 26] reported that"/>
 <result pre="in serum and saliva of treated and untreated children with" exact="migraine" post="without aura. 2. Materials and Methods 2.1. Study Subjects"/>
 <result pre="from their parents. 2.2. Inclusion and Exclusion Criteria Subjects with" exact="migraine" post="without aura, of both sexes and aged from 4–17"/>
 <result pre="excluded if they: Were aged &amp;lt;4 years or &amp;gt;18 years;" exact="obesity" post="(body mass index &amp;gt;95 percentiles), or had a history"/>
 <result pre="(body mass index &amp;gt;95 percentiles), or had a history of" exact="cardiovascular disease," post="hypertension, diabetes, hyperlipidemia, or stroke; a heavy smoker (&amp;gt;10"/>
 <result pre="bipolar disorders according to DSM-5; or had a history of" exact="substance abuse," post="mental retardation (intelligence quotient &amp;lt;70), genetic syndromes (e.g., Down"/>
 <result pre="liver or renal diseases, gastrointestinal disorders such as peptic or" exact="duodenal ulcer," post="dyspepsia, or heartburn and hypersensitivity to NSAIDs. Patients enrolled"/>
 <result pre="such as peptic or duodenal ulcer, dyspepsia, or heartburn and" exact="hypersensitivity" post="to NSAIDs. Patients enrolled were in migraine ictal phase."/>
 <result pre="or heartburn and hypersensitivity to NSAIDs. Patients enrolled were in" exact="migraine" post="ictal phase. 2.3. Experimental Protocol In a balanced recruitment"/>
 <result pre="2.3. Experimental Protocol In a balanced recruitment study, subjects with" exact="migraine" post="were enrolled in two groups: Treated-group: subjects with migraine"/>
 <result pre="with migraine were enrolled in two groups: Treated-group: subjects with" exact="migraine" post="without aura that were on pharmacological treatment at the"/>
 <result pre="observation (with magnesium or NSAIDs; i.e., acetaminophen). Untreated-group: subjects with" exact="migraine" post="without aura that presented to the observation for the"/>
 <result pre="mL) were collected in sterile tubes from both groups of" exact="migraine" post="subjects. In order to evaluate the expression of miRs"/>
 <result pre="3.1. Population During the study, we enrolled 78 subjects with" exact="migraine" post="(41 females and 38 males), age 13 ± 2.9"/>
 <result pre="± 2.9 years. After clinical evaluation and laboratory investigations, 35" exact="migraine" post="subjects (19 females and 16 males) fulfilled the inclusion"/>
 <result pre="blood samples). All enrolled subjects ( n = 24) presented" exact="migraine" post="without aura and were enclosed in the two groups:"/>
 <result pre="were enclosed in the two groups: Treated-group: n = 12" exact="migraine" post="subjects, 6 males and 6 females, between 7 and"/>
 <result pre="the acute attack ( Table 1). Untreated-group: n = 12" exact="migraine" post="subjects, 6 males and 6 females, between 4 and"/>
 <result pre="4 and 16 years (mean 11 ± 4.5 years), without" exact="migraine" post="pain, were enrolled as control-group ( Table 1). 3.2."/>
 <result pre="and serum frozen fractions obtained from all enrolled subjects with" exact="migraine" post="(treated and untreated) constitutively expressed both hsa-miR-34a-5p and hsa-miR-375,"/>
 <result pre="qRT-PCR revealed expression of hsa-miR-34a-5p and hsa-miR-375 in saliva of" exact="migraine" post="subjects enrolled in untreated subjects respect to both biological"/>
 <result pre="hsa-miR-375 in both serum and saliva of untreated patients with" exact="migraine" post="respect to both healthy people and treated migraine patients."/>
 <result pre="patients with migraine respect to both healthy people and treated" exact="migraine" post="patients. Even if some authors reported that CGRP could"/>
 <result pre="if some authors reported that CGRP could represent biomarkers of" exact="migraine" post="attack [ 9, 10, 12], its short half-life could"/>
 <result pre="More recently, miRNAs’ deregulation has been documented in patients with" exact="migraine" post="both during attacks and pain-free periods [ 32], highlighting"/>
 <result pre="highlighting the significance of these biomolecules in the pathophysiology of" exact="migraine" post="and their potential use as potential biomarkers. However, these"/>
 <result pre="miR-34a-5p and hsa-miR-375 in serum of children and adolescents with" exact="migraine" post="without aura suggesting their involvement in the pathogenetic mechanisms"/>
 <result pre="33]. Notably a recent study [ 25] showed that acute" exact="migraine" post="attacks in adults are associated with up-regulation of serum"/>
 <result pre="hsa-miR-34a-5p and hsa-miR-375 in saliva from children and adolescents with" exact="migraine" post="without aura respect to healthy subjects, suggesting that miRs"/>
 <result pre="readout of pathological processes arising into central nervous system since" exact="migraine" post="is known to be associated with activation and sensitization"/>
 <result pre="HCN3, NV3, and GPR158were found in DIANA-TOOLS database associated in" exact="trigeminal neuralgia" post="and targets of hsa-miR-34a-5p. In particular, HCN3 belong to"/>
 <result pre="by dosing biomarkers on saliva samples from young subjects with" exact="migraine" post="without aura could represent a clinical tool as mentioned"/>
 <result pre="of disease and of drug efficacy in young subjects with" exact="migraine" post="without aura and that saliva could be used to"/>
 <result pre="S.Z. subject’s enrolment and clinical evaluation, S.S. clinical test for" exact="migraine" post="history; A.V. laboratory test for microRNAs analysis; A.M., L.S.,"/>
 <result pre="Guidetti V. Effects of acetaminophen and ibuprofen in children with" exact="migraine" post="receiving preventive treatment with magnesium Headache 2014 54 313"/>
 <result pre="in periaqueductal gray matter as a potential biomarker for chronic" exact="migraine" post="Neurology 2019 92 e1076 e1085 10.1212/WNL.0000000000007047 30709968 8. Ferroni"/>
 <result pre="Calcitonin gene-related peptide in peripheral blood as a biomarker for" exact="migraine" post="Curr. Opin. Neurol. 2017 30 281 286 10.1097/WCO.0000000000000440 28234796"/>
 <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology 2013 81 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 11. Cernuda-Morollon"/>
 <result pre="as predictors of efficacy of Onabotulinumtoxin type A in chronic" exact="migraine" post="Headache 2014 54 987 995 10.1111/head.12372 24673487 12. Fan"/>
 <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann. Neurol. 1990 28 183 187 10.1002/ana.410280213 1699472"/>
 <result pre="OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic" exact="migraine" post="Pain 2015 156 820 824 10.1097/j.pain.0000000000000119 25735000 16. Kee"/>
 <result pre="M. Mezzetti A. Giamberardino M.A. Cipollone F. MicroRNA profiling in" exact="migraine" post="without aura: Pilot study Ann. Med. 2015 47 468"/>
 <result pre="in peripheral blood mononuclear cells from patients with type 2" exact="diabetes mellitus" post="Exp. Ther. Med. 2017 14 5589 5596 10.3892/etm.2017.5254 29285097"/>
 <result pre="17 2011 10.3390/ijms17122011 39. Pietrobon D. Moskowitz M.A. Pathophysiology of" exact="migraine" post="Ann. Rev. Physiol. 2013 75 365 391 10.1146/annurev-physiol-030212-183717 23190076"/>
 <result pre="P.J. Holland P.R. Divergent influences of the locus coeruleus on" exact="migraine" post="pathophysiology Pain 2019 160 385 394 10.1097/j.pain.0000000000001421 30371556 41."/>
 <result pre="Clinical characteristics of treated and untreated groups of subjects with" exact="migraine" post="without aura (MWA) and healthy group without MWA, herein"/>
 <result pre="miRNA Validated Target Genes Associated Disease hsa-miR-34a-5p HCN3, NAV3, GPR158" exact="trigeminal neuralgia" post="hsa-miR-375 MTPN -"/>
</results>
